Last update 01 Nov 2024

IL-3Rβ

Last update 01 Nov 2024

Basic Info

Synonyms

beta common cytokine receptor, beta-GM-CSF receptor, betaGMR

+ [10]

Introduction

Cell surface receptor that plays a role in immune response and controls the production and differentiation of hematopoietic progenitor cells into lineage-restricted cells. Acts by forming an heterodimeric receptor through interaction with different partners such as IL3RA, IL5RA or CSF2RA (PubMed:1495999). In turn, participates in various signaling pathways including interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor/CSF2 pathways. In unstimulated conditions, interacts constitutively with JAK1 and ligand binding leads to JAK1 stimulation and subsequent activation of the JAK-STAT pathway (PubMed:9516124).

Drugs associated with IL-3Rβ

Trabikibart

Target

IL-3Rβ

Mechanism

IL-3Rβ inhibitors

Active Org.

CSL Behring LLC

Originator Org.

CSL Ltd.

Active Indication

Asthma

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

ASM-8

Target

CCR3 x IL-3R x IL-3Rβ

Mechanism

CCR3 modulators [+2]

Active Org.-

Originator Org.

Syntara Ltd.

Active Indication-

Inactive Indication

Allergic asthma [+1]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with IL-3Rβ

NCT04082754 / CompletedPhase 1

A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Subjects With Mild-to-moderate Asthma and in Healthy Volunteers

This is a phase 1, first-in-human (FIH), multi-center, randomized, double-blind, placebo-controlled study of CSL311 in patients with mild-to-moderate asthma. The primary objective of this study is to assess the safety and tolerability of single ascending doses (SAD) and multiple ascending doses (MAD) of CSL311.

Start Date28 Nov 2019

Sponsor / Collaborator

CSL Behring LLC

NCT01380236 / WithdrawnPhase 2

A Phase II, Two-centre, Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Adult Subjects With Moderate to Severe Asthma

The purpose of the study is to determine the safety and tolerability of 8.0 mg of ASM8 when given daily for 14 days by the Aeroneb® Go nebulizer to subjects with moderate to severe asthma.

Start Date01 Nov 2011

Sponsor / Collaborator

Syntara Ltd.

EUCTR2011-000126-30-GB / Not yet recruitingNot Applicable

A phase II, multi-centre, single blind study to evaluate the safety, tolerability and explore the efficacy of 8.0 mg ASM8 inhaled daily for 14 days in adult subjects with moderate to severe asthma - Safety & Tolerability of 8mg ASM8 in moderate to severe asthmatics

Start Date07 Jun 2011

Sponsor / Collaborator

Syntara Ltd.

100 Clinical Results associated with IL-3Rβ

100 Translational Medicine associated with IL-3Rβ

0 Patents (Medical) associated with IL-3Rβ

279

Literatures (Medical) associated with IL-3Rβ

27 Sep 2024·Medicine

Transactivation DNA-binding protein–related genes were associated with salivary gland injury in primary Sjögren syndrome

Article

Author: Zhang, Naidan ; Yuan, Chengliang ; Zhang, Hongsheng ; Bao, Xiao

The purpose was to identify transactivation DNA-binding protein–related genes in salivary gland injury in primary Sjögren syndrome (pSS) in southwest China.We downloaded the datasets of GSE7451, GSE23117, and GSE40611. In order to screen the candidate genes, 2 kinds of machine learning algorithms were used. We collected blood from 28 patients and 20 controls to verify the expression of candidate genes using quantitative real-time polymerase chain reaction. The receiver operating characteristic curve was used to evaluate the diagnostic efficiency. Correlations between candidate genes and immune cells were examined.A total of 31 differentially expressed genes were obtained. Through different algorithms, 6 genes including IFIT1, CSF2RB, TRIM22, PPM1H, VAMP7, and C21orf2 were getted. Validation results suggested that the expression of CSF2RB, VAMP7, IFIT1, C21orf2, and TRIM22 was significantly increased in pSS. The area under the curve of CSF2RB was 0.937 and that of TRIM22 was 0.915. Immune infiltration analysis showed that the percentage of activated mast cells was lower than the controls (P = .025). Correlation analysis suggested that CSF2RB was associated with immune cell infiltration. The expression of CSF2RB was significantly upregulated, which could be related to the increase of γδ T cells.We revealed that CSF2RB could be the candidate gene of pSS. CSF2RB was involved by regulating various immune cells. The expression of CSF2RB was significantly upregulated, which was related to the increase of γδ T cells.

01 Jul 2024·Heliyon

Comprehensive analysis of single-cell RNA and bulk RNA sequencing based on M2 tumor-associated macrophage and angiogenesis-related genes to assess prognosis and therapeutic response in lung adenocarcinoma

Article

Author: Zhang, Junhang ; Liu, Anbang ; Wang, Xiaohuai ; Yan, Dongqing ; Liu, Gengqiu ; Wei, Li

M2 tumor-associated macrophage (M2 TAM), a crucial component of the tumor microenvironment, has a significant impact on tumor invasion and metastasis in the form of angiogenesis for lung adenocarcinoma (LUAD). In this study, both single-cell RNA and bulk RNA sequencing data were analyzed to identify 12 M2 TAM and angiogenesis-related genes (OLR1, CTSL, HLA-DPB1, NUPR1, ALOX5, DOCK4, CSF2RB, PTPN6, TNFSF12, HNRNPA2B1, NCL, and BIRC2). These genes were used to construct a prognostic signature, which was subsequently validated using an external cohort. Moreover, the immune profile analysis indicated that the low-risk group exhibited a distinct immune cell infiltration and relatively active status. Importantly, the prognostic signature was closely associated with PD-1, CTLA4, tumor mutation burden, and anti-cancer drug sensitivity. In summary, this study proposes a new prognostic signature for patients with LUAD based on M2 TAM and angiogenesis-related genes. The signature forecasts the prognosis of LUAD by an independent manner, reveals the potential molecular mechanisms involved in tumor immune-related functions, and offers appropriate clinical strategies for the treatment of patients with LUAD.

01 Jul 2024·Heliyon

Article

Author: Zhang, Junhang ; Liu, Anbang ; Wang, Xiaohuai ; Yan, Dongqing ; Liu, Gengqiu ; Wei, Li

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

IL-3Rβ

Basic Info

Related

Analysis